je.st
news
Tag: evaluating
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress
2013-04-23 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language: English Contact HTML: MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
updated
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
2013-04-22 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language: English Contact HTML: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: c
agreement
trial
combination
Evaluating Fiber Digestibility of Corn Co-Products
2013-03-07 20:51:00| National Hog Farmer
John Patience and Nestor A. Gutierrez, Iowa State University Studies at Iowa State University (ISU) evaluated the best ways to characterize fiber from corn co-products in order to determine the site of digestion in the pig and better understand its potential contribution to energy. The trials also evaluated the impact of including fiber from corn on growth performance and on the digestion and utilization of energy and nutrients in the diet. read more
Tags: fiber
evaluating
corn
digestibility
Evaluating Corn and Soybean Consumption Projections
2013-02-12 01:00:00| ThePigSite - Industry News
US - On 8 February, the USDA released new projections for marketing year consumption of US corn and soybeans. Prices will now be at least partially influenced by how closely the rate of consumption tracks these projections, writes Darrel Good.
Tags: consumption
evaluating
corn
projections
Evaluating evolutionary rates could shed light into functions of uncharacterized genes
2013-02-08 11:00:00| LifeSciencesWorld
[NEWS] Contact: Anita Srikameswaran SrikamAV@upmc.edu 412-578-9193 University of Pittsburgh Schools of the Health Sciences PITTSBURGH, Feb. 8, 2013 - Genes that have roles in the same biological pathways change their rate of evolution in parallel, a finding that could be used to discover their functions, said a researcher at the Univ…
Tags: light
rates
functions
evaluating
Sites : [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »